Search results for: Human soluble interleukin 2 receptor,IL 2sR
#12204787 // To Up
Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices.
This study was undertaken to investigate the role of cytokines in intrauterine contraception. Cervical mucus samples were obtained from 20 women with proven fertility 7, 14, 30, and 120 days after insertion of copper-T380 intrauterine devices (IUDs) for the determination of interleukin-2 (IL-2) soluble receptor (IL-2SR) and granulocyte macrophage colony stimulating factor (GM-CSF) concentrations. Both levels of IL-2SR and GM-CSF were significantly elevated after insertion of copper-releasing IUDs. This elevation remained significant through 6 months post-insertion. The mean-fold rise of GM-CSF compared to pre-insertion mean values amounted to 12.4, 11.8, 2.1, and 1.5 at 7, 14, 30, and 120 days post-insertion, respectively. The corresponding values for IL-2SR were 10.4, 8.8, 2.6, and 2.5, respectively. These results demonstrate enhanced local cytokines production in IUD users indicating local inflammatory reaction in the endometrium. This inflammatory reaction together with the cytotoxic effects of these cytokines may produce an environment which adversely affect embryo pre-implantation. This may explain the antifertility effect of copper IUDs.Amal Shobokshi, Mohamed Shaarawy
2327 related Products with: Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices.
1 mg5ug10 ug200ul5ug2ug2ug1 mg96T12ugRelated Pathways
#12022343 // To Up
Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
To measure markers of atherogenesis and thrombogenesis in patients with rheumatoid arthritis (RA) and in matched controls, and to relate these variables to markers of inflammation and endothelial activation, and to the presence of atherosclerosis.Solveig Wållberg-Jonsson, Jasmina Trifunovic Cvetkovic, Karl-Gösta Sundqvist, Ann Kari Lefvert, Solbritt Rantapää-Dahlqvist
2742 related Products with: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
100 1 mg1 kit1 kit5ug96 testsRelated Pathways
#10227112 // To Up
Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration.
Serum levels of interleukin-2 soluble receptor alpha (IL-2sR alpha), interleukin-6 (IL-6) and interleukin-1 receptor antagonist (IL-1ra) were determined both before and during neuroleptic administration in an 8-week treatment protocol for schizophrenia. In comparison with a control group, schizophrenia patients showed significantly higher serum levels of IL-2sR alpha, IL-6 and IL-1ra at weeks 0, 1, 4 and 8, and there was a significant negative correlation between the serum level of IL-2sR alpha at week 1 and the age at illness onset. Those of the schizophrenia patients who were neuroleptic-naive had significantly higher pretreatment serum levels of IL-2sR alpha, IL-6 and IL-1ra than the controls. There were significant positive correlations between the IL-2sR alpha levels at weeks 0 and 1, and the psychopathology scores, evaluated using the positive and negative syndrome scale at week 4. IL-6 levels at weeks 0, 1 and 4 were significantly and positively correlated with the duration of illness. The IL-1ra level at week 1 was significantly and positively correlated with positive symptoms at week 1. The present study supports the suggestion that changes in the immune system are involved in the pathophysiology of schizophrenia.K Akiyama
1880 related Products with: Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration.
100ug100ug100ug100ug200ul200ug100ug200ul 100ul100ug Lyophilized100ug100ug LyophilizedRelated Pathways
#7831505 // To Up
[Immunopathology of cytomegalovirus pneumonia and allograft rejection in lung transplantation. Group of Pulmonary Transplantation of the University Paris-Sud].
In order to better understand the immunopathology of acute complications of lung transplantation we have analysed the different parameters of cytotoxic cell and macrophage activation during the course of pulmonary allograft rejection and cytomegalovirus pneumonia. In transplanted patients presenting with an acute pulmonary allograft rejection, a cytomegalovirus pneumonia or no complication (control group), we have studied, first serum markers of immune activation: interleukin-2 soluble receptor (IL-2sR), neopterin, IL-6, TNF soluble receptors (TNF-sR55 and TNF-sR75). Secondly the intrapulmonary compartmentalisation of allogenic and antiviral responses were evaluated by studying bronchoalveolar lavage fluid (BAL). The level of IL-6 was measured in BAL supernatants and the gene expression of two cytokines (IL-1 beta and IL-6) and two markers of activated cytotoxic cells (granzyme B and perforin) were studied by in situ hybridisation on the alveolar cells. Acute pulmonary allograft rejection was characterised by the paucity of systemic stigmata of immune activation and by the intrapulmonary compartmentalisation of the inflammatory response principally expressed by an increase in alveolar concentration of IL-6, TNF-sR55 and TNF-sR75, and an increased expression of the IL-1 beta gene. Cytomegalovirus pneumonia is accompanied by an intense local and systemic inflammatory activity as evidenced by the serum level of IL-2sR, neopterin, TNF-sR55 and TNF-sR75, the alveolar concentration of IL-6, TNF-sR55 and TNF-sR75, and the expression of monokine (IL-1 beta, IL-6) and of cytotoxic mediator (granzyme b, perforin) genes by BAL cells. These mediators could participate in the elaboration of an acute or chronic inflammatory response which would be potentially deleterious for the graft.M Humbert, D Emilie
1681 related Products with: [Immunopathology of cytomegalovirus pneumonia and allograft rejection in lung transplantation. Group of Pulmonary Transplantation of the University Paris-Sud].
5 G1Related Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]